Abstract: This invention provides HIF-3? nucleic acid and protein sequences. Also provided are methods for using HIF-3? nucleic acids, proteins, fragments, antibodies, probes, and cells, to characterize HIF-3?, modulate HIF-3? cellular levels, induce angiogenesis, improve muscular function, and treat coronary and cardiac diseases in mammals.

Abstract: This invention provides HIF-3? nucleic acid and sequences. Also provided are methods for using HIF-3? nucleic acids, proteins, fragments, antibodies, probes, and cells, to characterize HIF-3?, modulate HIF-3? cellular levels, induce angiogenesis, improve muscular function, and treat coronary and cardiac diseases in mammals.

Abstract: The present invention relates to an occlusion device for treating an aneurysm, its use and a method for treating an aneurysm. The occlusion device comprises a detachable filling element and at least one radioactive source. The detachable filling element and the radioactive source are adapted to be inserted into a vessel at least in close proximity of a neck of an aneurysm. The radioactive source stimulates neointima formation for obstructing the neck of the aneurysm or filling up the aneurysm.

Abstract: The present invention relates to antisense oligonucleotides directed to the human cyclin E gene for inhibiting its expression, and to a method for inhibiting cellular proliferation. The antisense oligonucleotides of the present invention have been designed from the 5′ and 3′-untranslated region of the cyclin E gene for inhibiting the expression of the cyclin E gene. These antisense oligonucleotides can be used for research purposes, diagnostics and treatment of disease. Methods for specifically modulating cyclin E expression in cells and tissues using the antisense oligonucleotides are disclosed. Methods for diagnosis, detection and treatment of pathologies involving cyclin E gene are disclosed.

Abstract: The present invention relates to a radiolabeled DNA oligonucleotide, a method of preparation thereof and the therapeutic uses of this substance to prevent uncontrolled cellular proliferation. The invention also relates to devices incorporating the above radiolabeled DNA oligonucleotide for the therapeutic treatment of uncontrolled cellular proliferation. More specifically, the present invention is concerned with the prevention of restenosis by coronary delivery of radiolabeled DNA oligonucleotide at a dilatation site of an artery. This invention is also directed to a method of treatment of vascular proliferative diseases and/or other proliferative disorders such as cancer and related metastasis.